SalvaRx's (SALV) long term aim is to develop a pipeline of complementary cancer immunotherapy-focused products and technologies, activating the body's immune system to down-regulate tumour progression. Achieving a durable patient response to support long-term survival is essential for Pharma companies scouting new clinical assets. SALV's expanding product portfolio continues to create a substantial licensing or exit opportunity for investors.
